Nektar Therapeutics to Participate in Two Investor Conferences in March

About this update from Nektar Therapeutics

SAN FRANCISCO , Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami . TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m. Eastern Time / 6:10 a.m. Pacific Time – link here 2026 Jefferies Biotech on the Beach Summit in Miami – March 9-11, 2026 – company management to be available for one-on-one meetings The presentation will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . A replay of the presentation will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California . For further information, visit www.nektar.com and follow us on LinkedIn . For Investors: Vivian Wu 628-895-0661 [email protected] Corey Davis , Ph.D. LifeSci Advisors, LLC [email protected] 212-915-2577 For Media: Jonathan Pappas LifeSci Communications 857-205-4403 [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-march-302696266.html SOURCE Nektar Therapeutics

View stock analysis, news, and events for Nektar Therapeutics